2 Result: SCYNEXIS
Q2: SCYNEXIS Surpasses Forecasts; Nogin Misses the Mark
August 14th, 2023
SCYNEXIS, Inc. (Nasdaq: SCYX), a biotechnology company, reported second-quarter 2023 earnings of $2.46 per share, surpassing the consensus estimate of $1.55 per share. The company posted quarterly sales of $131.50 million, exceeding analysts' project. Read more
Major Announcements in the Industry: Momentus Secures SpaceX Deal, Clearmind Medicine Receives Trial Approval, and SCYNEXIS Enters Exclusive License Agreement with GSK
May 12th, 2023
In recent updates, several companies have made significant announcements in their respective fields. Here's a breakdown of the latest developments: Momentus Inc. (Nasdaq: MNTS) has entered into a contract with SpaceX, securing a port reservation o. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
February 27th, 2026February 26th, 2026
Member Login